Patent intelligence · US
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
Patent details — US 12365688
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 22, 2025
- Expiration
- Jul 17, 2045
- Applicant
- Revolution Medicines, Inc.
- Claims
- 36
- CPC classes
- A61P, A61P35/00
Quick answer
US 12365688 (Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors) is held by Revolution Medicines, Inc.. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Expiration
- Claims
- 36
- CPC classes
- A61P, A61P35/00
More from Revolution Medicines, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12365688?
US 12365688 (Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors) is held by Revolution Medicines, Inc.. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12365688?
Revolution Medicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 12365688 expire?
Our index shows an expiration date of Jul 17, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.